Summit Therapeutics up after Fast Track designation, trial enrollment completion

Shares of Summit Therapeutics are up $1.34, or 7%, to $19.95 after the company announced it has completed enrollment in the Phase 3 HARMONi clinical trial evaluating ivonescimab plus platinum-doublet chemotherapy and also announced that the U.S. Food and Drug Administration has granted Fast Track designation for the proposed use of ivonescimab in combination with platinum-based chemotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR mutation, who have experienced disease progression following EGFR-TKI therapy.